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Accepted 23 February 2012This study aimed to determine in obese women if endocannabinoid receptor antagonism has
effects on fatty acid and triglyceridemetabolismand insulin sensitivitywhichare independent
from the metabolic effects of weight loss. Fourteen obese (BMI=33.0±0.5 kg/m2) (mean±SEM)
Caucasian post-menopausal women, aged 57.8±4.7 years were studied. The women were
randomised to 2 groups, one group received the endocannabinoid receptor antagonist
rimonabant (20 mg/d) for 12 weeks. A control group achieved the same weight loss by a
hypocaloric dietary intervention over 12 weeks. Palmitate production rate (Ra), a measure of
lipolysis, and palmitate oxidation rate, and VLDL1 and VLDL2 triglyceride (TG) kinetics, were
measuredusing isotopic tracersbeforeandafter the intervention.Weight losswasnotdifferent
in the 2 groups; 2.6±0.5 kg with rimonabant and 3.1±1.0 kg in the control group. Palmitate Ra
increased with rimonabant with no change in the control group (p=0.03 between groups).
Palmitateoxidationrate increasedwithrimonabantbutdecreasedinthecontrolgroup (p=0.005
between groups). VLDL1 TG secretion rate decreased in the control group and increased in the
rimonabant group (p=0.008 between groups). There was no significant effect on insulin
sensitivity. This study suggests that endocannabinoid receptor antagonism for 12 weeks in
obese women increased lipolysis and fatty acid oxidation. The increase in VLDL1 TG secretion
ratemay bedue to the increase in lipolysiswhich exceeded the increase in fatty acid oxidation.
© 2012 Elsevier Inc. All rights reserved.1. Introduction
The endocannabinoid system is involved in the physiological
control of food intake and energy balance [1]. It is overactive inte; IHCL, intrahepatocellu





n to this manuscript.
er Inc. All rights reservedhuman obesity [2] and in diet-induced obese mice [3,4]. Mice
with a genetic deletion in the CB1 cannabinoid receptor are
leaner than their pair fed wild type littermates andwhen fed a
high fat diet do not become obese or develop insulinlar lipid; IMCL, intramyocellular lipid; MCR, metabolic clearance
penditure; SR, secretion rate; TEE, total energy expenditure; TG,
.
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diture. The CB1 antagonist rimonabant (SR141716) reduced
food intake transiently in diet-induced obese mice, but a
decrease in body weight was prolonged, also suggesting an
effect on energy expenditure [6]. In ob/ob mice treated for 7
days with rimonabant, basal oxygen consumption increased
37% compared to control mice [7].
Three studies in obese subjects (BMI 33–38 kg/m2) com-
pleting 12 months of treatment with rimonabant (20 mg/d)
showed a mean weight loss from baseline of 8.5 kg, accom-
panied by a decrease in plasma TG and an increase in insulin
sensitivity [8-10]. Calculation of the expectedmetabolic effects
of the body weight loss suggested that 50% of the improve-
ments in TG and insulin sensitivity could not be attributed to
weight loss per se [10].
Since weight loss can cause significant changes in metab-
olism, to determine the direct effects of rimonabant rather
than those due to weight loss, this study compared changes in
fatty acid and triglyceride metabolism in a rimonabant-
treated group and a control group treated only with diet
with weight loss matched for that achieved in the rimonabant
group. To investigate whether rimonabant could induce
weight loss due to effects on energy expenditure, energy
intake was maintained at pre-treatment levels in the treat-
ment group.2. Methods
2.1. Study design
This study was registered with ClinicalTrials.gov
(NCT00584389) and approved by the UK Medicines and
Healthcare Products Regulatory Agency (Eudract 2006-
006424-18), the East Kent Ethics Committee and University
of Surrey Ethics Committee. All subjects provided written
informed consent. The study was powered for 30 obese (BMI
30–35 kg/m2) Caucasian post-menopausal women, rando-
mised into two groups. The treatment group (n=15) was to
receive rimonabant (20 mg/d) for 12 weeks with energy intake
matched to their energy requirements, determined during a 4
week run-in pre-treatment period. The control group (n=15)
was to follow a dietary intervention to achieve the sameTable 1 – Energy balance, hormones, lipids and insulin sensitiv
Rimonabant Group
Week 0 Week 12
Energy intake (kcal/day) 1991±99 1963±73
REE (kcal/day) 1434±59 1436±50
Glucose (mmol/l) 5.6±0.2 5.4±0.1
GIR/I (μg/kg/min/ [pmol/l]) 5.07±1.09 6.04±1.41
Triglyceride (mmol/l) 1.6±0.6 1.7±0.5
Cholesterol (mmol/l) 5.6±0.5 5.4±0.7
HDL-Cholesterol (mmol/l) 1.39±0.13 1.49±0.13‡
Adiponectin (μg/ml) 12.0±1.4 11.9±1.5
Leptin ng/ml 23.5±2.9 20.6±3.0⁎
GIR/I, glucose infusion rate/insulin. Significantly different from run-in peweight loss as the rimonabant group. Exclusion criteria are
shown in the Supplement. The European Medicines Agency
withdrew marketing authorisation for rimonabant in 2008,
rimonabant was withdrawn from the market by Sanofi-
aventis, and the study was terminated. Studies had been
completed in 14 women randomised into the rimonabant (age
58.1±1.9 years; BMI 32.9±0.7) and control group (age 57.4±1.9
years; BMI 33.0±0.8) (n=7/group).
After recruitment and randomisation, participants en-
tered a 4 week run-in period (see Supplement). At the end of
this period the following measurements were made; whole
body fat by bioimpedance, resting energy expenditure (REE)
by indirect calorimetry, insulin sensitivity with a euglycemic
hyperinsulinemic clamp, palmitate Ra, Ox and metabolic
clearance rate (MCR) with an infusion of 13C palmitate and
13C acetate, VLDL1 and VLDL2-TG secretion and FCR, with an
intravenous bolus of 2H5 glycerol and IHCL and IMCL by
magnetic resonance spectroscopy (see Supplement). These
measurements were repeated after 12 weeks.
For laboratorymethodsanddataanalysis see theSupplement.
2.2. Statistical analysis
The results are presented as means±SEM. Within group
changes were analysed by paired t test and changes between
groups by t test using SPSS (version 16). Non parametric data
were logarithmically transformed before analysis.3. Results
During the run-in period TEE was not significantly different
from energy intake confirming participants were not under-
reporting energy intake. Reported energy intake was main-
tainedwith rimonabant for 13weeks anddecreased in controls
(Table 1) (Fig. 2, Supplement) due to a decrease in fat and
carbohydrate intake (Table 2, Supplement).Weight loss, which
was 2.6±0.5 kg with rimonabant (p<0.003), and 3.1±1.0 kg in
controls (p<0.03) was not different between groups. Therewas
a similar reduction inwaist circumference and fatmass but no
change in IHCL and IMCL in both groups (Table 1, Supplement).
REE tended to decrease in controls (p=0.055), as expected with
weight loss but was maintained with rimonabant despiteity.
Control Group Δ rimonabant
vs Δ control










riod, †p<0.05; ⁎p<0.01; ‡p=0.05.
Table 2 – Palmitate and VLDL kinetics.
Rimonabant Group Control Group Δ rimonabant
vs Δ control
Week 0 Week 12 Week 0 Week 12
FFA mmol/l 0.84±0.09 0.83±0.06 0.80±0.09 0.81±0.08 NS
Glycerol μmol/l 147±15 124±17 141±15 145±12 NS
Palmitate μmol/l 152±13 157±13 139±10 140±18 NS
Palmitate Ra μmol/min 189±6 229±17† 208±24 189±18 p=0.03
Palmitate MCR ml/min 1286±104 1541±146⁎ 1500±158 1467±185 NS
Palmitate ox μmol/min 64±4 81±6⁎ 77±8 65±4‡ p=0.005
VLDL1 TG mmol/l 1.01±0.39 1.16±0.32 0.64±0.04 0.48±0.06§ p=0.03
VLDL2 TG mmol/l 0.26±0.07 0.30±0.06 0.18±0.03 0.17±0.03 NS
VLDL1 TG FCR pools/d 14.6±2.1 16.2±3.4 12.8±1.4 14.0±2.3 NS
VLDL2 TG FCR pools/d 13.4±1.4 13.5±3.0 14.6±1.7 17.7±2.9 NS
VLDL1 TG SR g/d 25.8±4.5 36.7±8.9‡ 19.5±2.3 14.6±2.0§ p<0.008
VLDL2 TG SR g/d 8.0±1.6 9.2±1.6 6.3±1.3 6.6±1.2 NS
SR, secretion rate; FCR, fractional catabolic rate; MCR, metabolic clearance rate; ox, oxidation rate Ra, rate of appearance. n=6 for palmitate
kinetics in the rimonabant group due to compromised venous access during the palmitate tracer infusion in 1 subject; significantly different
from 0 weeks, †p<0.05, ⁎p=0.05, ‡p=0.06, §p=0.07.
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was not statistically significant (Table 1).
The change in palmitate Ra over 12 weeks was
significantly different between groups (p=0.03) with a
within group increase (p<0.05) with rimonabant (Table 2).
Palmitate MCR also increased (p=0.05) with rimonabant.
There was no change in these measurements in the control
group. Palmitate Ox increased with rimonabant and de-
creased in controls with a difference between groups
(p=0.005). Palmitate Ra, and Ox were also different between
groups when expressed per kg of fat free mass (p=0.03,
p=0.01). When expressed per kg of fat mass palmitate Ra
increased with rimonabant (p=0.02) and was different
between groups (p=0.04).
Plasma TG decreased in controls (p<0.05) but did not
change with rimonabant (Table 1). VLDL1 TG concentration
decreased in controls (p=0.07). VLDL1 SR increased with
rimonabant and decreased in controls (p<0.008 between
groups) (Table 2).4. Discussion
This study demonstrated that the CB1 receptor antagonist
rimonabant had metabolic effects which were independent
of weight loss. Using stable isotope techniques it was shown
that palmitate Ra, a measure of lipolysis, and palmitate MCR
increased after rimonabant treatment for 12 weeks. Palmi-
tate Ox also increased with rimonabant, in contrast to the
controls where palmitate Ox decreased. VLDL TG kinetics
were also different in the 2 groups with an increase in VLDL1
TG SR with rimonabant but a decrease in the control group
suggesting that the increased lipolysis with rimonabant
treatment may have driven an increase in hepatic TG
synthesis. REE decreased in the controls but did not decrease
with rimonabant despite similar weight loss suggesting an
effect on energy expenditure.
This is the first demonstration that palmitate oxidation is
increased with a CB1 receptor antagonist in humans and
importantly confirms previous animal studies. In rats fed ahigh fat diet, rimonabant treatment increased the oxygen
consumption of liver mitochondria and increased fatty acid
entry into liver mitochondria via CPT I [11]. Increased hepatic
CPT1 activity has also been reported inmice fed a high fat diet
and treated with rimonabant [12]. The peripheral CB1 receptor
antagonist, AM6545 has also been shown to increase fat
oxidation, in mice fed either a standard laboratory diet or a
high fat diet [13].
This is also the first demonstration in humans that a
CB1 receptor antagonist increases lipolysis. Adipocytes
express CB1 receptors and endocannabinoids have been
shown to inhibit lipolysis via inhibition of adenylate cyclase
[14]. CB1 receptors are also present on peripheral sympa-
thetic nerve terminals where they mediate inhibition of
norepinephrine release [15]. Blockade of these receptors by
rimonabant is another possible mechanism for the increase
in lipolysis in adipose tissue which is highly innervated by
the SNS.
The decrease in plasma TG in the controls was in VLDL1
due to a decrease in VLDL1 TG secretion. Previous studies
have also shown weight loss due to caloric restriction to
decrease VLDL TG secretion [16]. Despite similar weight loss
with rimonabant VLDL1 TG secretion increased. Since the
increase in palmitate Ra was greater than the increase in
palmitate oxidation rate with rimonabant, VLDL1 secretion
may have increased due to an increased delivery of fatty
acids to the liver driving VLDL1 synthesis. This contrasts
with the large rimonabant clinical trials in which plasma
TG decreased after 52 weeks when weight was beginning to
stabilize. After 12 weeks [8-10], the rate of weight loss
would be expected to be high. Treatment of both diet
induced mice and ob/ob mice with the peripheral CB1
receptor antagonist, AM6545 for 7 days was also shown to
increase TG secretion [13].
One aim of the study had been to investigate whether
weight loss would occur due to increased energy expendi-
ture if calorie intake could be maintained in the rimonabant
group. The lack of a decrease in REE with rimonabant,
despite weight loss, suggests there was an effect on energy
expenditure. Strack et al (2011) also found total EE measured
1223M E T A B O L I S M C L I N I C A L A N D E X P E R I M E N T A L 6 1 ( 2 0 1 2 ) 1 2 2 0 – 1 2 2 3with double labelled water did not decrease following
pharmacologic inhibition of the CB1 receptor in a canine
model despite an 11% reduction in body weight, whereas
total EE decreased in a food restricted control group with
only 6% weight loss [17].
This is a small study, reduced in size due to the
withdrawal of rimonabant during the trial and therefore
may be limited by lack of power to detect some differences.
Nevertheless the demonstration of metabolic changes in a
small study shows the powerful effect of rimonabant on
lipolysis and fatty acid oxidation in obese humans which
could be detected using isotopic tracers. Further studies of
the role of the endocannabinoid system in the control of fatty
acid metabolism and energy balance may lead to the
development of anti-obesity drugs which do not have the
unacceptable side effects of rimonabant.
Supplementary materials related to this article can be
found online at doi:10.1016/j.metabol.2012.02.012.Author contributions
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